Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06047171

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Led by Alentis Therapeutics AG · Updated on 2025-11-20

80

Participants Needed

49

Research Sites

198 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to learn if a new drug that might help protect and preserve kidney function in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). AAV is a type of autoimmune disease where the body's own immune system attacks itself, and in the case of AAV the body attacks its own small blood vessels. There are many small blood vessels in the kidneys meaning the kidneys are commonly affected in AAV. The main questions it aims to answer are: * Is the new drug well tolerated and safe? * Can the new drug protect and preserve kidney functions when is added to standard therapy? Researchers will compare the following groups to see how the new drug is tolerated and what effect to preserve kidney tissue has: * Group A: Standard treatment + ALE.F02 low dose infusions * Group B: Standard treatment + ALE.F02 high dose infusions * Group C: Standard treatment + ALE.F02 maximum dose infusions * Group D: Standard treatment + placebo infusions (inactive substance) The Treatment period will consist of 24 weeks beginning on Day 1, during which time participants will receive 13 infusions of the study medicine, along with standard therapy for kidney inflammation due to AAV. During the treatment period, participants will have the following assessments: * A brief physical examination focusing on their skin any pre-existing medical conditions that you have. * Collection of blood and urine samples for routine safety tests and to assess renal function. * Collection of blood samples: * To measure the amount of study medicine in their blood. This is called pharmacokinetics (PK) and it is tested to see how study medicine enters, moves through, and exits the body. * To test for antidrug antibodies (ADA). To check if their body create antibodies against the study medicine, as this could reduce its effect. * To measure biomarkers. Biomarkers are specific compounds in the body (can be protein, hormones, or genetic molecules) that indicate normal or abnormal processes taking place in your body and may be a sign of an underlying condition or disease (for example glucose levels are used as biomarker in managing diabetes). They are used to see how well the body responds to a treatment for a disease or condition. * Collection of urine to measure urine markers of vasculitis/inflammation called biomarkers. * Urine pregnancy test. A urine pregnancy test is a quick medical test that can tell if a woman is pregnant or not by checking for a hormone which is produced during pregnancy, usually in the urine. * Chest High Resolution Computed Tomography (HRCT) scan to check whether they have vasculitis affecting their lungs. A CT scan uses special x-ray equipment to take detailed pictures of body tissues and organs to diagnose and monitor conditions in various parts of the body. For the CT scan, they will need to lie still on a table. At Week 24 a second lung CT scan will be performed for participants whose initial scan showed lung vasculitis to see whether your lung vasculitis is getting better or ongoing/worse.

CONDITIONS

Official Title

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patients 18 years or older of any race or ethnicity with a Clinical Frailty Scale score less than 7 within 3 months before RPGN onset attributed to AAV
  • Willing and able to comply with study requirements and provide informed consent
  • Willing to have a kidney biopsy performed before study drug administration at Week 6 or have a historical biopsy within 45 days prior
  • Newly diagnosed with RPGN within 45 days before starting study drug, with loss of kidney function (eGFR between 10 and 50 mL/min/1.73 m2) and history of proteinuria and/or hematuria associated with illness
  • Suspected RPGN due to AAV at screening with positive ANCA test (anti-MPO or anti-PR3)
  • Body weight of at least 30 kg
  • Female participants must not be pregnant or breastfeeding and either use highly effective birth control during the study and for at least 30 days after last dose or be of non-childbearing potential
  • Female participants must agree not to donate eggs for 6 months after last dose
  • Male participants must agree to use contraception or abstinence during the study and for 90 days after last dose
  • Male participants must agree to abstain from sperm donation during the study and for 90 days after last dose
Not Eligible

You will not qualify if you...

  • History of previous RPGN that has resolved or relapsed
  • Positive test for anti-glomerular basement membrane antibodies
  • Evidence of active or latent tuberculosis
  • Chronic infections that could worsen with RPGN or its standard treatments
  • Active hepatitis B, hepatitis C, or HIV infection
  • Use of prohibited medications
  • Prior standard therapy exceeding high-dose glucocorticoid limits or planned treatment with avacopan
  • Poor venous access
  • Participation in investigational drug or device studies within specified timeframes before study
  • History of autoimmune skin disorders except those related to AAV
  • Diagnosis of systemic lupus erythematosus-AAV overlap or eosinophilic granulomatosis with polyangiitis
  • Uncontrolled serious diseases unrelated to RPGN or AAV
  • Recent live vaccine within 30 days or other vaccines within 7 days before first dose except influenza or pneumococcal
  • Employment or family relation to study staff
  • Not recovered from major surgery complications
  • Active or recent alcohol or substance abuse
  • Recent cancer diagnosis except certain skin cancers
  • Severe lung bleeding with low oxygen or needing ventilatory support
  • Dialysis or plasma exchange within 7 days before screening
  • Known allergy to study drug or its ingredients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 49 locations

1

Vseobecna fakultni nemocnice v Praze

Prague, Czechia, 128 08

Actively Recruiting

2

Institut klinicke a experimentalni mediciny

Prague, Czechia, 140 21

Actively Recruiting

3

Aalborg University Hospital

Aalborg, Denmark, 9000

Actively Recruiting

4

Aarhus University Hospital

Aarhus, Denmark, 8200

Actively Recruiting

5

Rigshospitalet

Copenhagen, Denmark, 56 2100

Actively Recruiting

6

Odense University Hospital

Odense, Denmark, 5000

Actively Recruiting

7

Centre Hospitalier Boulogne sur Mer

Boulogne-sur-Mer, Cedex, France, 62200

Actively Recruiting

8

CHU Bordeaux - Hopital Pellegrin

Bordeaux, France, 33000

Actively Recruiting

9

CHRU de Brest - Hopital de la Cavale Blanche

Brest, France, 29200

Actively Recruiting

10

CHU Grenoble-Alpes - Hopital Michallon

La Tronche, France, 38700

Actively Recruiting

11

CHU de Nantes - Hotel-Dieu

Nantes, France, 44000

Actively Recruiting

12

CHU de Nimes

Nîmes, France, 31000

Actively Recruiting

13

AP-HP Hopital Pitie-Salpetriere

Paris, France, 75013

Actively Recruiting

14

AP-HP Hopital Cochin

Paris, France, 75014

Actively Recruiting

15

CHU de Toulouse - Hopital Rangueil

Toulouse, France, 31400

Actively Recruiting

16

Centre Hospitalier de Valenciennes

Valenciennes, France, 59300

Actively Recruiting

17

Charite Universitaetsmedizin Berlin

Berlin, Germany, 10117

Actively Recruiting

18

Universitaetsklinikum Koeln (AoeR)

Cologne, Germany, 50931

Actively Recruiting

19

Universitaetsklinikum Carl Gustav Carus Dresden

Dresden, Germany, 01307

Actively Recruiting

20

Universitaetsklinikum Essen

Essen, Germany, 45147

Actively Recruiting

21

Medizinische Hochschule Hannover (MHH)

Hanover, Germany, 30625

Actively Recruiting

22

Universitaetsklinikum Leipzig

Leipzig, Germany, 04103

Actively Recruiting

23

Universitaetsklinikum Schleswig-Holstein - Campus Luebeck

Lübeck, Germany, 23562

Actively Recruiting

24

Klinikum der Ludwig-Maximilians-Universitaet Muenchen

München, Germany, 80802

Actively Recruiting

25

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

Bergamo, Italy, 24127

Actively Recruiting

26

Azienda Ospedaliero-Universitaria Careggi

Florence, Italy, 50134

Actively Recruiting

27

IRCCS Ospedale San Raffaele

Milan, Italy, 20132

Actively Recruiting

28

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

Rome, Italy, 00168

Actively Recruiting

29

APSS Ospedale Santa Chiara di Trento

Trento, Italy, 38122

Actively Recruiting

30

Fundacio Puigvert

Barcelona, Spain, 08025

Actively Recruiting

31

Hospital Universitari de Bellvitge

Barcelona, Spain, 08907

Actively Recruiting

32

Hospital Universitari Arnau de Vilanova

Lleida, Spain, 25198

Actively Recruiting

33

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

34

Hospital Regional Universitario de Malaga

Málaga, Spain, 29001

Actively Recruiting

35

Linkoping University Hospital

Linköping, Sweden, 581 85

Actively Recruiting

36

University Hospital of Umea

Umeå, Sweden, 907 37

Actively Recruiting

37

Kantonsspital Baden AG

Baden, Switzerland, 5404

Actively Recruiting

38

Inselspital, Universitaetsspital Bern

Bern, Switzerland, 3010

Actively Recruiting

39

Kantonsspital St. Gallen

Sankt Gallen, Switzerland, 9000

Actively Recruiting

40

Hôpital Fribourgeois-Freiburger Spital

Villars-sur-Glâne, Switzerland, 1752

Withdrawn

41

Ankara Etlik City Hospital

Ankara, Keçiören, Turkey (Türkiye)

Actively Recruiting

42

Marmara University Medical Faculty Hospital

Istanbul, Turkey (Türkiye)

Actively Recruiting

43

Kocaeli University Medical School - Internal Medicine - Nephrology

Kocaeli, Turkey (Türkiye)

Actively Recruiting

44

Erciyes University Faculty of Medicine

Melikgazi, Turkey (Türkiye)

Actively Recruiting

45

Queen Elizabeth Hospital Birmingham

Birmingham, United Kingdom, B152GW

Actively Recruiting

46

Cambridge University - Addenbrooke's Hospital

Cambridge, United Kingdom, CB2 0QQ

Actively Recruiting

47

Royal Liverpool University Hospital

Liverpool, United Kingdom, L78YE

Actively Recruiting

48

Imperial College Healthcare NHS Trust

London, United Kingdom, W21NY

Actively Recruiting

49

Royal Preston Hospital

Preston, United Kingdom, PR2 9HT

Actively Recruiting

Loading map...

Research Team

M

Mohamed Benabed

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Rescue of Nephrons With ALE.F02 (RENAL-F02) | DecenTrialz